Asenapine: a new antipsychotic option

Area of Science:

• Psychopharmacology
• Neuroscience

Background:

• Asenapine is a psychopharmacologic agent approved for schizophrenia and bipolar I disorder.
• Its efficacy and comparative advantages require thorough examination.

Purpose of the Study:

• To evaluate the efficacy of asenapine compared to placebo and active controls in schizophrenia and bipolar I disorder.
• To analyze factors influencing asenapine's therapeutic utility, including efficacy, receptor binding, administration, compliance, and cost.

Main Methods:

• Four 6-week studies assessed asenapine for schizophrenia using placebo and active controls (risperidone, olanzapine, haloperidol).
• Two 3-week trials evaluated asenapine for bipolar I disorder against olanzapine and placebo.

Main Results:

• Asenapine demonstrated efficacy over placebo in 2 schizophrenia trials and both bipolar I disorder trials.
• No significant efficacy advantage was observed compared to other antipsychotic agents.
• Barriers to compliance include twice-daily dosing, pre-administration restrictions, sublingual administration requirements, and low bioavailability if swallowed.

Conclusions:

• Asenapine is effective for acute schizophrenia and bipolar I disorder treatment but lacks a clear efficacy advantage over existing antipsychotics.
• Administration and compliance challenges, alongside a lack of cost-effectiveness, present significant considerations for its clinical use.